IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImageneBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.00−0.04 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $64.65M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.54 (−46.95%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ImageneBio, Inc. saw revenue fall 77.1% to $800.00K over fiscal 2025.
Revenue
$800.00K
-77.1% vs. a year earlier
Operating income
-$58.96M
TTM Q2 2026
EPS, diluted
-$9.64
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $64.65M
- P/E ratio
- –
- Price to sales
- 80.81
- Price to book
- 0.46
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $800.00K
- Net income
- -$52.48M
- EPS, diluted
- -$9.64
- Book value per share
- $8.79
- Diluted shares
- 16M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$58.96M
Net income
-$52.48M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months